← Russell 3000 cross-section

BSX BOSTON SCIENTIFIC CORP

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$68.4bn
Revenue TTM
$21.0bn
Net income TTM
$3.7bn
Free cash flow
$3.6bn
Composite score
65.8
Sector rank
#183

Valuation

P / E
18.7
EV / EBITDA
12.5
EV / sales
3.3
FCF yield
5.30%
Earnings yield vs 10-yr
0.63pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
17.5%
EBITDA margin
26.5%
ROE
14.7%
ROIC
15.9%
Revenue growth
13.5%

Insider activity, last 90 days

Net open-market
$9.49m
Buyers
4
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our biliary franchise, led by our AXIOS™ Stent and Delivery System, and our core GI franchise. In the second quarter and first six months of 2026, reported net sales growth was relatively flat, primarily driven by underperformance in our stone franchise as a result of volume-based-procurement in China, and commercial disruption in our sacral neuromodulation franchise. …BOSTON SCIENTIFIC CORP, 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →